- Global Pharma News & Resources

Disease – Modifying Agents Market By Drug Class (Interferon Beta-1α/β, Natalizumab, Mitoxantrone) and By Therapy Type (Monotherapy, Combination Therapy) – Forecast 2021-2031

250 Pages Disease – Modifying Agents Market Survey by Fact MR, A Leading Business and Competitive Intelligence Provider

In the struggle to slow the progression of disease in many inflammatory conditions such as rheumatoid arthritis, psoriasis, and psoriatic arthritis, the disease-modifying agent class, including treatments such as anti-TNF agents and immunomodulators, the market is experiencing significant growth. There are 15 FDA-approved non-biologics and biologics disease-modifying agents competing in the market today with an estimated 18 biosimilars or standard agents currently testing.

The Market Research Survey by Fact.MR, highlights the key reasons behind increasing saled and demand of Disease – Modifying Agents. Disease – Modifying Agents market drivers and constraints, threats and opportunities, regional segmentation and opportunity assessment, end-use/application prospects review are addressed in the Disease – Modifying Agents market survey report. The survey report provides a comprehensive analysis of Disease – Modifying Agents market key trends and insights on Disease – Modifying Agents market size and share.

To Get In-depth Insights Request for Brochure here –

How is the Disease-Modifying Agents Market of Europe flourishing?

The European medical services framework has a developing medical services framework, with a multi-payer system that is to a great extent funded by the government. It is the second most successful healthcare system after the U.S in the world. One in three postmenopausal women has osteoporosis in Europe. In Western Europe, rheumatoid arthritis prevalence is 346.8/100,000. However, the incidence rates are in Western Europe 20.4/100,000. According to a 2010 European study, the average annual cost of medical, non-medical, and indirect (work productivity loss-related) was higher in patients with systemic sclerosis than in rheumatoid arthritis and/or psoriatic arthritis patients. The significant-high population in Europe with a considerably rising need for better treatment will give significant growth to the disease-modifying agents market. With the presence of many key players, growth in the European countries creates a huge opportunity for the disease-modifying agents market to grow.

Key Segments of Disease-Modifying Agents Market Covered in the Report

  • Based on drug class, the global Disease-Modifying Agents market has been segmented as
    • Interferon Beta-1α/β
    • Natalizumab
    • Mitoxantrone
    • Glatiramer Acetate
    • Fingolimod
    • Dimethyl Fumarate
    • Ocrelizumab
    • Teriflunomide
    • Ciclosporin
    • Cyclophosphamide
    • Hydroxychloroquine
    • Leflunomide
    • Methotrexate
    • Mycophenolate
    • Sulfasalazine
    • Others
  • Based on Indication, the global Disease-Modifying Agents market has been segmented as
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Systemic Sclerosis
    • Cancer

Request Customized Report as Per Your Requirements –

Key questions answered in Disease – Modifying Agents Market Survey Report:

  1. What is the current scenario and key trends in Disease – Modifying Agents Market?
  2. What are the key strategies companies are adopting to increase their consumer base?
  3. What are the key categories within the Disease – Modifying Agents segments and their future potential?
  4. What are the major Disease – Modifying Agents Market drivers and their expected impact during the short, medium, and long terms?
  5. What is the Disease – Modifying Agents Market size and what are the opportunities for the key players?

Essential Takeaways from the this Market Report

  • Comparison of prominent players operating in the market.
  • Recent developments and key strategies adopted by key players.
  • Study of the micro and macro-economic growth indicators.
  • Impact of the various factors on the value chain.
  • Evaluation of current Disease – Modifying Agents market size, forecast and technological advancements within the industry.
  • Current Insights influencing the scenario and key trends in Disease – Modifying Agents market.

Enquire Before Buying Here –

The Report Covers Exhaustive Analysis On:

  • Disease – Modifying Agents Market Drivers, Segments and Restraints.
  • Disease – Modifying Agents Market Survey and Dynamics
  • Disease – Modifying Agents Market Size & Demand
  • Disease – Modifying Agents Key Trends/Issues/Challenges
  • Disease – Modifying Agents Sales, Competition & Companies involved

Explore Fact.MR’s Coverage on the Healthcare Domain:

Medical Coding Market– According to the latest research by Fact.MR, the medical coding market is set to witness significant growth during 2021-2031. Medical coding has always been in demand and is expected to remain at a steady growth in the forecasted period. Medical coding has been in demand in the U.S. as is designed to support Electronic Health Records (EHRs).

Ambulance Services Market According to the latest research by Fact.MR, the Ambulance Services market is set to witness steady growth during 2021-2031. The market is moderately fragmented and the demand for Ambulance Services will witness stable growth owing to the rising number of medical emergencies, a rapid rise in hospitals visits due to this pandemic as well as regular doctor visits.

mRNA Sequencing Market– According to the latest research by Fact.MR, the mRNA Sequencing market is set to witness steady growth during 2021-2031. The market has been a highly fragmented market developing at a gradual rate and is expected to witness lucrative growth with the increasing utilization of methodologies by major participants; the market is anticipated to increase over the projected skyline.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

The post Disease – Modifying Agents Market By Drug Class (Interferon Beta-1α/β, Natalizumab, Mitoxantrone) and By Therapy Type (Monotherapy, Combination Therapy) – Forecast 2021-2031 appeared first on Latest Market Reports.

Editor Details

Last Updated: 24-Nov-2021